- CEO
- Zheng Wei Pang
- Full Time Employees
- 1,623
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Jiangxi Fengxin Industrial Park Yichun JX China 330700
- IPO Date
- Mar 31, 2017
- Business
- Jiangxi Synergy Pharmaceutical Co., Ltd. (300636.SZ) manufactures and sells active pharmaceutical ingredients (APIs), pharmaceutical intermediates, raw materials, and fine chemicals worldwide, with core products including gabapentin, candesartan cilexetil, celecoxib, aceclofenac, rebamipide, venlafaxine HCl, azilsartan medoxomil, dabigatran etexilate mesylate, amlodipine besylate, mirabegron, empagliflozin, and intermediates for anticoagulants, antihypertensives, anti-inflammatories, antiepileptics, antidepressants, and antiviral drugs; the company serves domestic and international markets in Europe, North America, Japan, South Korea, and other regions. Founded in 2004 and headquartered in Yichun, Jiangxi Province, China, with manufacturing facilities in Fengxin Industrial Park, it operates in the healthcare sector focusing on drug manufacturers for specialty and generic pharmaceuticals, employing approximately 1,362 people. Recent developments include obtaining South Korean regulatory approval and pharmaceutical registration certificates for amlodipine besylate, azilsartan potassium (Amiasartan potassium), and mirabegron in 2025; achieving GMP compliance certification from Jiangxi authorities for empagliflozin in March 2025; securing European marketing authorization for celecoxib; receiving a patent for a triazine ketone compound in April 2025; and reporting first-quarter 2025 revenue of CNY 187 million despite a year-on-year decline.